172 related articles for article (PubMed ID: 20735140)
41. Reversal effects of nomegestrol acetate on multidrug resistance in adriamycin-resistant MCF7 breast cancer cell line.
Li J; Xu LZ; He KL; Guo WJ; Zheng YH; Xia P; Chen Y
Breast Cancer Res; 2001; 3(4):253-63. PubMed ID: 11434876
[TBL] [Abstract][Full Text] [Related]
42. Discovery of new pyrimidopyrrolizine/indolizine-based derivatives as P-glycoprotein inhibitors: Design, synthesis, cytotoxicity, and MDR reversal activities.
Shawky AM; Abdalla AN; Ibrahim NA; Abourehab MAS; Gouda AM
Eur J Med Chem; 2021 Jun; 218():113403. PubMed ID: 33823396
[TBL] [Abstract][Full Text] [Related]
43. A unique P-glycoprotein interacting agent displays anticancer activity against hepatocellular carcinoma through inhibition of GRP78 and mTOR pathways.
Kuo TC; Chiang PC; Yu CC; Nakagawa-Goto K; Bastow KF; Lee KH; Guh JH
Biochem Pharmacol; 2011 May; 81(9):1136-44. PubMed ID: 21371443
[TBL] [Abstract][Full Text] [Related]
44. 20(S)-Protopanaxadiol (PPD) analogues chemosensitize multidrug-resistant cancer cells to clinical anticancer drugs.
Liu J; Wang X; Liu P; Deng R; Lei M; Chen W; Hu L
Bioorg Med Chem; 2013 Jul; 21(14):4279-87. PubMed ID: 23683834
[TBL] [Abstract][Full Text] [Related]
45. Dual P-Glycoprotein and CA XII Inhibitors: A New Strategy to Reverse the P-gp Mediated Multidrug Resistance (MDR) in Cancer Cells.
Teodori E; Braconi L; Bua S; Lapucci A; Bartolucci G; Manetti D; Romanelli MN; Dei S; Supuran CT; Coronnello M
Molecules; 2020 Apr; 25(7):. PubMed ID: 32290281
[TBL] [Abstract][Full Text] [Related]
46. First total synthesis of protoapigenone and its analogues as potent cytotoxic agents.
Lin AS; Nakagawa-Goto K; Chang FR; Yu D; Morris-Natschke SL; Wu CC; Chen SL; Wu YC; Lee KH
J Med Chem; 2007 Aug; 50(16):3921-7. PubMed ID: 17622129
[TBL] [Abstract][Full Text] [Related]
47. Novel Pt(IV) complexes to overcome multidrug resistance in gastric cancer by targeting P-glycoprotein.
Cao X; Li R; Xiong H; Su J; Guo C; An T; Zong H; Zhao R
Eur J Med Chem; 2021 Oct; 221():113520. PubMed ID: 34029775
[TBL] [Abstract][Full Text] [Related]
48. Structure-activity relationship (SAR) study of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and the potential of the lead against multidrug resistance in cancer treatment.
Aridoss G; Zhou B; Hermanson DL; Bleeker NP; Xing C
J Med Chem; 2012 Jun; 55(11):5566-81. PubMed ID: 22582991
[TBL] [Abstract][Full Text] [Related]
49. Altered activity of MDR-reversing agents on KB3-1 cells transfected with Gly(185)-->Val human P-glycoprotein.
Watanabe T; Uchiyama N; Roninson IB; Cohen D; Atadja P
Int J Oncol; 2000 Sep; 17(3):579-86. PubMed ID: 10938401
[TBL] [Abstract][Full Text] [Related]
50. Reversal of multidrug resistance by Marsdenia tenacissima and its main active ingredients polyoxypregnanes.
To KKW; Wu X; Yin C; Chai S; Yao S; Kadioglu O; Efferth T; Ye Y; Lin G
J Ethnopharmacol; 2017 May; 203():110-119. PubMed ID: 28363522
[TBL] [Abstract][Full Text] [Related]
51. Tangeretin, a citrus pentamethoxyflavone, antagonizes ABCB1-mediated multidrug resistance by inhibiting its transport function.
Feng SL; Yuan ZW; Yao XJ; Ma WZ; Liu L; Liu ZQ; Xie Y
Pharmacol Res; 2016 Aug; 110():193-204. PubMed ID: 27058921
[TBL] [Abstract][Full Text] [Related]
52. 5-Oxo-hexahydroquinoline derivatives as modulators of P-gp, MRP1 and BCRP transporters to overcome multidrug resistance in cancer cells.
Ranjbar S; Khonkarn R; Moreno A; Baubichon-Cortay H; Miri R; Khoshneviszadeh M; Saso L; Edraki N; Falson P; Firuzi O
Toxicol Appl Pharmacol; 2019 Jan; 362():136-149. PubMed ID: 30391378
[TBL] [Abstract][Full Text] [Related]
53. Circumvention of multidrug resistance by a quinoline derivative, MS-209, in multidrug-resistant human small-cell lung cancer cells and its synergistic interaction with cyclosporin A or verapamil.
Shrivastava P; Hanibuchi M; Yano S; Parajuli P; Tsuruo T; Sone S
Cancer Chemother Pharmacol; 1998; 42(6):483-90. PubMed ID: 9788575
[TBL] [Abstract][Full Text] [Related]
54. A Y
Wang Y; Jiang Z; Yuan B; Tian Y; Xiang L; Li Y; Yang Y; Li J; Wu A
Biomater Sci; 2019 Nov; 7(11):4748-4757. PubMed ID: 31508613
[TBL] [Abstract][Full Text] [Related]
55. Novel virosecurinine bivalent mimetics as potent reversal agents against P-glycoprotein-mediated multidrug resistance.
Hou W; Meng Y; Xu XF; Huang ZX; Liu J; Wang ZY; Lin J; Chen WM
Eur J Med Chem; 2019 Dec; 183():111726. PubMed ID: 31585275
[TBL] [Abstract][Full Text] [Related]
56. Sensitization of multidrug resistant (MDR) cancer cells to vinblastine by novel acridones: correlation between anti-calmodulin activity and anti-MDR activity.
Mayur YC; Padma T; Parimala BH; Chandramouli KH; Jagadeesh S; Gowda NM; Thimmaiah KN
Med Chem; 2006 Jan; 2(1):63-77. PubMed ID: 16787357
[TBL] [Abstract][Full Text] [Related]
57. Design and synthesis of new potent N,N-bis(arylalkyl)piperazine derivatives as multidrug resistance (MDR) reversing agents.
Dei S; Coronnello M; Bartolucci G; Manetti D; Romanelli MN; Udomtanakunchai C; Salerno M; Teodori E
Eur J Med Chem; 2018 Mar; 147():7-20. PubMed ID: 29421572
[TBL] [Abstract][Full Text] [Related]
58. Dasatinib reverses the multidrug resistance of breast cancer MCF-7 cells to doxorubicin by downregulating P-gp expression via inhibiting the activation of ERK signaling pathway.
Chen T; Wang C; Liu Q; Meng Q; Sun H; Huo X; Sun P; Peng J; Liu Z; Yang X; Liu K
Cancer Biol Ther; 2015; 16(1):106-14. PubMed ID: 25482933
[TBL] [Abstract][Full Text] [Related]
59. N-methylation of anthracyclines modulates their cytotoxicity and pharmacokinetic in wild type and multidrug resistant cells.
Gate L; Couvreur P; Nguyen-Ba G; Tapiero H
Biomed Pharmacother; 2003 Sep; 57(7):301-8. PubMed ID: 14499178
[TBL] [Abstract][Full Text] [Related]
60. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein.
Sikic BI; Fisher GA; Lum BL; Halsey J; Beketic-Oreskovic L; Chen G
Cancer Chemother Pharmacol; 1997; 40 Suppl():S13-9. PubMed ID: 9272128
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
